US Pharma MarketingNovo Nordisk expands in China and Czech; Cellares boosts Series D by $50M
Novo Nordisk invests ~$380M in Czech manufacturing and $29.4M in China; Cellares grows Series D to $327M; Eisai gets support; Siegfried opens plant in Minden, Germany. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Plus more from Eisai and Siegfried.
🧱 Novo Nordisk's expansions: Novo Nordisk has invested around $380 million to expand its manufacturing facility in Bohumil, Central Bohemia, in the Czech Republic. Meanwhile ...
Source: Endpoints News